Niagen Bioscience Inc
NASDAQ:NAGEBiotechnology
+$0.11 today
- Market cap
- $153.64M
- Beta
- 2.06
- P/E (TTM)
- 14.9
- EPS (TTM)
- $0.23
Volume 0.52M
Average 0.86M
NAGE Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Niagen Bioscience IncNASDAQ: NAGE
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 20.0% from a year ago
Cash & equivalents stood at $66.55M at the end of Q1 FY2026, up 20.0% from a year earlier and up 2.7% from the prior quarter. Over 3 fiscal years it compounded at +47.3% a year.
Context
- Cash & equivalents amounted to 58.2% of total assets at the end of Q1 FY2026, down 10.0 pp from a year earlier.
- Cash & equivalents increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +20.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 64.79M USD
- Year-over-year change
- +45.6%
- 4-year CAGR
- +23.3%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 64.79M | +45.6% |
| FY2024 | 2024-12-31 | 44.51M | +63.8% |
| FY2023 | 2023-12-31 | 27.17M | +33.9% |
| FY2022 | 2022-12-31 | 20.29M | -27.6% |
| FY2021 | 2021-12-31 | 28.02M | — |
Cash & Equivalents vs competitors
How NAGE compares with its peers on the latest reported figures
- NAGE's Mar 2026 cash & equivalents of $66.55M is the 6th highest of the 10 companies compared; the peer median is $95.6M.
- Its year-over-year change of +20.0% is the 4th highest of 9, against a peer median of -8.7%.
- Cash & equivalents amounts to 58.2% of total assets for NAGE, versus a peer median of 34.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $329.46M | -21.2% | -24.4% | 94.2% | |
| Mar 2026 | $281.5M | -60.9% | +1.0% | 90.1% | |
| Dec 2025 | $229.34M | — | — | 68.4% | |
| Mar 2026 | $162.64M | +43.5% | +26.9% | 44.9% | |
| Mar 2026 | $95.6M | +156.0% | -1.6% | 34.3% | |
NAGENiagen Bioscience Inc | Mar 2026 | $66.55M | +20.0% | +47.3% | 58.2% |
| Mar 2026 | $52.55M | +3.8% | +26.8% | 9.9% | |
| Mar 2026 | $40.1M | +702.2% | -29.7% | 15.8% | |
| Mar 2026 | $24.41M | -46.6% | +18.4% | 4.8% | |
| Mar 2026 | $15.23M | -88.3% | -29.2% | 4.5% | |
| Peer median (excluding NAGE) | $95.6M | -8.7% | -0.3% | 34.3% | |
Competitors are the stored peer set for NAGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 28.02M | 20.29M | 27.17M | 44.51M | 64.79M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 5.23M | 8.48M | 5.23M | 7.77M | 9.74M |
| Inventory | 13.6M | 14.68M | 14.53M | 9.19M | 20.42M |
| Other Current Assets | 200K | 3.12M | 2.6M | 2.63M | 1.85M |
| Total Current Assets | 48.91M | 46.57M | 49.53M | 64.1M | 96.81M |
| Property, Plant & Equipment (Net) | 7.36M | 6.32M | 4.54M | 3.45M | 3.52M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 857K | 671K | 510K | 359K | 5.66M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 723K | 497K | 383K | 368K | 425K |
| Total Non-current Assets | 8.94M | 7.49M | 5.43M | 4.18M | 9.6M |
| Total Assets | 57.84M | 54.06M | 54.96M | 68.28M | 106.41M |
| Account Payables | 10.42M | 9.68M | 10.23M | 8.53M | 10.8M |
| Short-term Debt | 0 | 0 | 0 | 0 | 1M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 161K | 157K | 195K | 611K | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 8.12M |
| Total Current Liabilities | 17.61M | 17.87M | 20.62M | 17.95M | 19.92M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 4.35M | 3.96M | 3.31M | 2.58M | 2.67M |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 5.47M |
| Total Non-current Liabilities | 8.5M | 7.52M | 5.89M | 4.24M | 9.95M |
| Total Liabilities | 26.11M | 25.39M | 26.51M | 22.18M | 29.87M |
| Common Stock | 68K | 74K | 75K | 77K | 79K |
| Retained Earnings | (168.95M) | (185.49M) | (190.46M) | (181.91M) | (164.53M) |
| Accumulated OCI | (2K) | (3K) | (4K) | (4K) | (9K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 31.73M | 28.67M | 28.46M | 46.09M | 76.53M |
| Total Debt | 4.7M | 4.26M | 3.28M | 2.65M | 2.82M |
| Net Debt | (23.32M) | (16.03M) | (23.9M) | (41.86M) | (61.97M) |
Niagen Bioscience Inc
NASDAQ:NAGE
Intrinsic Alpha fair value
Locked
Current Price
$1.94
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.